Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP)

Consortium for Improving Survival of Lymphoma trial

Jeongkuk Seo, Won Seog Kim, Jinseok Kim, Seok Jin Kim, Jae Hoon Lee, Jun Shik Hong, Gyeong Won Lee, Sung Yong Oh, Ji Hyun Lee, Dok Hyun Yoon, Won Sik Lee, Hyo Jung Kim, Jae Yong Kwak, Hye Jin Kang, Jae Cheol Jo, Yong Park, Ho Sup Lee, Hyo Jin Kim, Cheolwon Suh

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background Rituximab plus cyclophosphamide, vincristine, and prednisone (R-CVP) is one of the effective chemotherapeutic regimens for patients with advanced stage marginal zone lymphoma (MZL). However, prognostic factors that affect the outcome of treatment for MZL are not well understood. Methods Between August 2006 and June 2013, patients with newly diagnosed stage III and IV MZL treated with R-CVP as a first-line therapy from 15 institutions were retrospectively analyzed. Patients' clinical and laboratory data at diagnosis were collected by review of medical records. Results A total of 80 patients were analyzed. Bone marrow involvement was observed in 30% cases. Twelve patients (15%) had nodal MZL, and 41.3% patients exhibited multiple mucosa- associated lymphoma tissue sites. Overall response rate was 91.3%, including 73.8% achieving complete response. Advanced MZL patients treated with R-CVP showed a 3-year progression-free survival (PFS) rate of 69.6%. Prognostic markers significantly affecting PFS in univariate analysis were platelet to lymphocyte ratio (PLR, < 95 vs. ≥95, P=0.014), serum albumin (≤3.9 vs. > 3.9 g/dL, P =0.008), and the International Prognostic Index (IPI) score (1 vs. 2-4, P =0.032). In multivariate analysis, only PLR ( < 95 vs. ≥95, HR 0.367, 95% CI, 0.139-0.971, P =0.043) was an independent risk factor for PFS. Conclusion PLR ≥95 at diagnosis is an independent prognostic marker for PFS in advanced stage MZL patients treated with R-CVP. This marker may aid clinicians in predicting the response to R-CVP chemotherapy in stage III and IV MZL patients.

Original languageEnglish
Pages (from-to)200-206
Number of pages7
JournalBlood Research
Volume52
Issue number3
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Vincristine
Prednisone
Combination Drug Therapy
Cyclophosphamide
Lymphoma
Blood Platelets
Lymphocytes
Survival
Disease-Free Survival
Rituximab
Medical Records
Mucous Membrane
Multivariate Analysis
Survival Rate
Bone Marrow
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Seo, Jeongkuk ; Kim, Won Seog ; Kim, Jinseok ; Kim, Seok Jin ; Lee, Jae Hoon ; Hong, Jun Shik ; Lee, Gyeong Won ; Oh, Sung Yong ; Lee, Ji Hyun ; Yoon, Dok Hyun ; Lee, Won Sik ; Kim, Hyo Jung ; Kwak, Jae Yong ; Kang, Hye Jin ; Jo, Jae Cheol ; Park, Yong ; Lee, Ho Sup ; Kim, Hyo Jin ; Suh, Cheolwon. / Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP) : Consortium for Improving Survival of Lymphoma trial. In: Blood Research. 2017 ; Vol. 52, No. 3. pp. 200-206.
@article{bb36213aa8cf4134bc2462073625b331,
title = "Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial",
abstract = "Background Rituximab plus cyclophosphamide, vincristine, and prednisone (R-CVP) is one of the effective chemotherapeutic regimens for patients with advanced stage marginal zone lymphoma (MZL). However, prognostic factors that affect the outcome of treatment for MZL are not well understood. Methods Between August 2006 and June 2013, patients with newly diagnosed stage III and IV MZL treated with R-CVP as a first-line therapy from 15 institutions were retrospectively analyzed. Patients' clinical and laboratory data at diagnosis were collected by review of medical records. Results A total of 80 patients were analyzed. Bone marrow involvement was observed in 30{\%} cases. Twelve patients (15{\%}) had nodal MZL, and 41.3{\%} patients exhibited multiple mucosa- associated lymphoma tissue sites. Overall response rate was 91.3{\%}, including 73.8{\%} achieving complete response. Advanced MZL patients treated with R-CVP showed a 3-year progression-free survival (PFS) rate of 69.6{\%}. Prognostic markers significantly affecting PFS in univariate analysis were platelet to lymphocyte ratio (PLR, < 95 vs. ≥95, P=0.014), serum albumin (≤3.9 vs. > 3.9 g/dL, P =0.008), and the International Prognostic Index (IPI) score (1 vs. 2-4, P =0.032). In multivariate analysis, only PLR ( < 95 vs. ≥95, HR 0.367, 95{\%} CI, 0.139-0.971, P =0.043) was an independent risk factor for PFS. Conclusion PLR ≥95 at diagnosis is an independent prognostic marker for PFS in advanced stage MZL patients treated with R-CVP. This marker may aid clinicians in predicting the response to R-CVP chemotherapy in stage III and IV MZL patients.",
author = "Jeongkuk Seo and Kim, {Won Seog} and Jinseok Kim and Kim, {Seok Jin} and Lee, {Jae Hoon} and Hong, {Jun Shik} and Lee, {Gyeong Won} and Oh, {Sung Yong} and Lee, {Ji Hyun} and Yoon, {Dok Hyun} and Lee, {Won Sik} and Kim, {Hyo Jung} and Kwak, {Jae Yong} and Kang, {Hye Jin} and Jo, {Jae Cheol} and Yong Park and Lee, {Ho Sup} and Kim, {Hyo Jin} and Cheolwon Suh",
year = "2017",
month = "1",
day = "1",
doi = "10.5045/br.2017.52.3.200",
language = "English",
volume = "52",
pages = "200--206",
journal = "Blood Research",
issn = "2287-979X",
publisher = "Korean Society of Hematology",
number = "3",

}

Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP) : Consortium for Improving Survival of Lymphoma trial. / Seo, Jeongkuk; Kim, Won Seog; Kim, Jinseok; Kim, Seok Jin; Lee, Jae Hoon; Hong, Jun Shik; Lee, Gyeong Won; Oh, Sung Yong; Lee, Ji Hyun; Yoon, Dok Hyun; Lee, Won Sik; Kim, Hyo Jung; Kwak, Jae Yong; Kang, Hye Jin; Jo, Jae Cheol; Park, Yong; Lee, Ho Sup; Kim, Hyo Jin; Suh, Cheolwon.

In: Blood Research, Vol. 52, No. 3, 01.01.2017, p. 200-206.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP)

T2 - Consortium for Improving Survival of Lymphoma trial

AU - Seo, Jeongkuk

AU - Kim, Won Seog

AU - Kim, Jinseok

AU - Kim, Seok Jin

AU - Lee, Jae Hoon

AU - Hong, Jun Shik

AU - Lee, Gyeong Won

AU - Oh, Sung Yong

AU - Lee, Ji Hyun

AU - Yoon, Dok Hyun

AU - Lee, Won Sik

AU - Kim, Hyo Jung

AU - Kwak, Jae Yong

AU - Kang, Hye Jin

AU - Jo, Jae Cheol

AU - Park, Yong

AU - Lee, Ho Sup

AU - Kim, Hyo Jin

AU - Suh, Cheolwon

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background Rituximab plus cyclophosphamide, vincristine, and prednisone (R-CVP) is one of the effective chemotherapeutic regimens for patients with advanced stage marginal zone lymphoma (MZL). However, prognostic factors that affect the outcome of treatment for MZL are not well understood. Methods Between August 2006 and June 2013, patients with newly diagnosed stage III and IV MZL treated with R-CVP as a first-line therapy from 15 institutions were retrospectively analyzed. Patients' clinical and laboratory data at diagnosis were collected by review of medical records. Results A total of 80 patients were analyzed. Bone marrow involvement was observed in 30% cases. Twelve patients (15%) had nodal MZL, and 41.3% patients exhibited multiple mucosa- associated lymphoma tissue sites. Overall response rate was 91.3%, including 73.8% achieving complete response. Advanced MZL patients treated with R-CVP showed a 3-year progression-free survival (PFS) rate of 69.6%. Prognostic markers significantly affecting PFS in univariate analysis were platelet to lymphocyte ratio (PLR, < 95 vs. ≥95, P=0.014), serum albumin (≤3.9 vs. > 3.9 g/dL, P =0.008), and the International Prognostic Index (IPI) score (1 vs. 2-4, P =0.032). In multivariate analysis, only PLR ( < 95 vs. ≥95, HR 0.367, 95% CI, 0.139-0.971, P =0.043) was an independent risk factor for PFS. Conclusion PLR ≥95 at diagnosis is an independent prognostic marker for PFS in advanced stage MZL patients treated with R-CVP. This marker may aid clinicians in predicting the response to R-CVP chemotherapy in stage III and IV MZL patients.

AB - Background Rituximab plus cyclophosphamide, vincristine, and prednisone (R-CVP) is one of the effective chemotherapeutic regimens for patients with advanced stage marginal zone lymphoma (MZL). However, prognostic factors that affect the outcome of treatment for MZL are not well understood. Methods Between August 2006 and June 2013, patients with newly diagnosed stage III and IV MZL treated with R-CVP as a first-line therapy from 15 institutions were retrospectively analyzed. Patients' clinical and laboratory data at diagnosis were collected by review of medical records. Results A total of 80 patients were analyzed. Bone marrow involvement was observed in 30% cases. Twelve patients (15%) had nodal MZL, and 41.3% patients exhibited multiple mucosa- associated lymphoma tissue sites. Overall response rate was 91.3%, including 73.8% achieving complete response. Advanced MZL patients treated with R-CVP showed a 3-year progression-free survival (PFS) rate of 69.6%. Prognostic markers significantly affecting PFS in univariate analysis were platelet to lymphocyte ratio (PLR, < 95 vs. ≥95, P=0.014), serum albumin (≤3.9 vs. > 3.9 g/dL, P =0.008), and the International Prognostic Index (IPI) score (1 vs. 2-4, P =0.032). In multivariate analysis, only PLR ( < 95 vs. ≥95, HR 0.367, 95% CI, 0.139-0.971, P =0.043) was an independent risk factor for PFS. Conclusion PLR ≥95 at diagnosis is an independent prognostic marker for PFS in advanced stage MZL patients treated with R-CVP. This marker may aid clinicians in predicting the response to R-CVP chemotherapy in stage III and IV MZL patients.

UR - http://www.scopus.com/inward/record.url?scp=85029885171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029885171&partnerID=8YFLogxK

U2 - 10.5045/br.2017.52.3.200

DO - 10.5045/br.2017.52.3.200

M3 - Article

VL - 52

SP - 200

EP - 206

JO - Blood Research

JF - Blood Research

SN - 2287-979X

IS - 3

ER -